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SHORT COMMUNICATION
Cancer Registration
The Thames Cancer Registry, Clifton Avenue, Belmont, Sutton, Surrey SM2 SPY, UK.
Sir - In their article entitled 'The completeness of Cancer
Registration in follow-up Studies - a cautionary note', Hunt
and Coleman (1987) rightly point out that delays occur in
cancer registration. Nevertheless, as their paper shows,
nearly half of the apparently missed cases were the result of
processing delays at OPCS and the NHSCR. The remainder
(excluding the case resident in Scotland), were unregistered
on average 5 years after diagnosis. In fact, this situation
could have been anticipated before the study began by
considering the delay in publication of the England and
Wales Cancer Registration Statistics for 1983 (series MBI
no. 15, HMSO), which appeared as recently as December,
1986.
Of the 11 cases, 3 were private patients. Because cancer is
not statutorily notifiable, it is difficult for NHS employees to
gain access to non-NHS premises, and private hospitals are
unlikely to spare staff for this job. At present, it would seem
little can be done about such cases unless the consultants
themselves notify the registry.
Of the remaining cases, 8 were treated at the Royal
Marsden Hospital. What is not generally appreciated is that
the very existence of such a specialist institution can cause
low registration rates and delays in registration. This may be
because case notes have become sequestered in clinics or
Clinical Trials Offices or in other places unknown or
inaccessible to the Registry clerks, and may partly explain
the delays in breast cancer notification noted by Swerdlow.
(Another explanation is that breast cancer has relatively long
survival, hence patients missed while in hospital will not be
registered until the Registry receives a death certificate,
perhaps years after diagnosis.) In addition, such hospitals
often have their own Registry and this, having lower priority
than clinical treatment will also cause delays in registration,
especially if the Regional Registry relies on the Hospital
Registry for notification of cases.
Although the authors correctly point out that their
estimate of completeness of cancer registration of 72%
cannot be assumed to be indicative of the situation in the
Thames regions, whose residents were over-represented in the
sample, it is difficult to reconcile this low figure with the
OPCS data that the authors also cite, which show that the
SW Thames region has the highest SRR for breast cancer in
the country. Moreover, routinely-produced mortality data
(which are compiled independently of cancer registration
statistics) show that mortality from breast cancer in the SW
Thames region is not unduly high, the SMR being 106 in
1981. This does not argue in favour of the breast cancer
epidemnic in whose existence we would have to believe if both
Hunt and Coleman's estimate of completeness of regis-
tration, and our own high registration rates are correct. It
might, of course, be suggested that higher survival rates in
SW Thames could allow all three observations (i.e., the
SRR, SMR and Hunt & Coleman's estima.te) to be accepted;
however, we know of no evidence of such superior survival.
It is our view that if notification is sought directly from
the Regional Registries rather than from NHSCR,
investigators should be able to minimise delay and this
would also help the Registries themselves to identify
bottlenecks in the registration process. Otherwise, without
legal obligation and extra funds, there would seem to be
little else that can be done at present.
Yours etc.,
P.B. Silcocks, H. Thornton-Jones & R.G. Skeet
The Thames Cancer Registry,
Clifton Avenue, Belmont,
Sutton, Surrey SM2 5PY, UK.
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Drs Hunt & Coleman reply:
Sir - Investigators following up individuals in a cohort
through the NHSCRs need other measures of the efficiency
of the cancer registration scheme than the speed with which
it publishes national incidence rates; this involves additional
delays in programming and publication which have often
been long, and which have no bearing on the completeness
of cancer registration. Thus, it is not clear how such
publication delays could have enabled us to anticipate that
half the missing cancers were unregistered, and that most of
them would probably never have been registered, except
perhaps at death. Nor does the speed of publication tell us
anything about the last link in the notification chain, - that
between OPCS and NHSCR. We sought to provide a simple
but quantitative insight into the nature and causes of delays
in notification, both as constructive criticism of cancer
registration and as a guide to investigators who rely solely
on the NHSCR notification system to ascertain cancers in
their studies.
We agree that access for registry staff to records in private
hospitals may be difficult, and that sequestration of hospital
records away from routine filing systems (e.g., for clinical
trials) may cause undue delays in registration. We also agree
that investigators should help registries identify problems in
cancer registration, but it is not clear that legal obligation to
report cancer would improve completeness. Of 77
population-based cancer registries surveyed in 1982, the 36
(47%) with voluntary reporting were by no means the least
complete, and there was no change in completeness when
Finland switched from voluntary to compulsory reporting in
1960 (Muir & Demaret, 1982).
We stressed in our paper that the figure of 72% (36/50)
could not be intercepted as an estimate of the completeness
of breast cancer registration, either nationally or in the
Thames region; it is therefore inappropriate to deduce an
improbable 'breast cancer epidemic' from the paper on the
basis of such a misinterpretation.
It is not always possible for investigators to seek
notification of cancers in particular individuals directly fromCANCER REGISTRATION 237
regional cancer registries. Few UK registries would have the
resources to meet regular demands of this kind, and
investigators studying national cohorts in the UK would
have to deal with up to 18 regional registries: it is clearly
preferable for a single centre such as the NHSCR to provide
this service. Our brief report was an attempt to identify some
of the problems in this system, including those at cancer
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